-transparent.png){kind=logo}
In a randomized, double-blind, group comparative study, 100 asthmatic patients known to be responsive to cromolyn sodium were treated either with pelletized cromolyn (cromolyn sodium, 20 mg) or with cromolyn blend, Intal (cromolyn sodium, 20 mg + lactose, 20 mg). There was no statistically significant difference between the two treatment groups for asthma severity, breathlessness on exertion, cough, the number of inhalations needed to obtain the dose from the capsule, and morning peak flow. No local or systemic side effects were encountered during the 6-month duration of the study. It is concluded that pelletized cromolyn offers most of the advantages of cromolyn therapy without the need for the patients to inhale lactose at the same time. Also, pelletized cromolyn has a distinct therapeutic advantage for use in lactose-in-tolerant patients.
D V Vakil, and
A Ayiomamitis, and
N Nizami, and
R M Nizami
March 1972,
The Journal of asthma research,
D V Vakil, and
A Ayiomamitis, and
N Nizami, and
R M Nizami
August 1974,
JAMA,
D V Vakil, and
A Ayiomamitis, and
N Nizami, and
R M Nizami
August 1990,
The Journal of pediatrics,
D V Vakil, and
A Ayiomamitis, and
N Nizami, and
R M Nizami
October 1984,
Pediatrics,
D V Vakil, and
A Ayiomamitis, and
N Nizami, and
R M Nizami
February 1983,
European journal of clinical microbiology,
D V Vakil, and
A Ayiomamitis, and
N Nizami, and
R M Nizami
February 1988,
The Journal of allergy and clinical immunology,
D V Vakil, and
A Ayiomamitis, and
N Nizami, and
R M Nizami
January 1985,
Revue d'odonto-stomatologie,
D V Vakil, and
A Ayiomamitis, and
N Nizami, and
R M Nizami
March 1982,
International journal of clinical pharmacology, therapy, and toxicology,
D V Vakil, and
A Ayiomamitis, and
N Nizami, and
R M Nizami
March 1970,
American journal of obstetrics and gynecology,
D V Vakil, and
A Ayiomamitis, and
N Nizami, and
R M Nizami
January 1988,
Drugs,
